Detalhe da pesquisa
1.
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.
N Engl J Med
; 389(3): 205-214, 2023 Jul 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37272521
2.
Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials.
J Allergy Clin Immunol
; 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38431226
3.
Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma.
J Allergy Clin Immunol
; 2024 Jan 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38272375
4.
Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 (RIPK1) inhibitor eclitasertib (SAR443122) in patients with severe COVID-19: a phase 1b, randomized, double-blinded, placebo-controlled study.
Respir Res
; 25(1): 107, 2024 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38419035
5.
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.
N Engl J Med
; 378(26): 2475-2485, 2018 06 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29782224
6.
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
N Engl J Med
; 378(26): 2486-2496, 2018 06 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29782217
7.
Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma.
Ann Allergy Asthma Immunol
; 126(5): 584-592.e1, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33465455
8.
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Lancet
; 394(10209): 1638-1650, 2019 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31543428
9.
Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis.
Allergy
; 75(1): 148-157, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31306495
10.
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.
J Am Acad Dermatol
; 82(2): 377-388, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31374300
11.
Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP.
Rhinology
; 58(1): 10-17, 2020 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31671432
12.
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
N Engl J Med
; 375(24): 2335-2348, 2016 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27690741
13.
Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma.
J Allergy Clin Immunol
; 142(1): 171-177.e1, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29355679
14.
3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD.
Eur Respir J
; 58(4)2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34675035
15.
CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.
Am J Respir Crit Care Med
; 191(9): 1001-11, 2015 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25695403
16.
Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study.
Lancet Respir Med
; 12(1): 45-54, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37956679
17.
Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials.
Nat Med
; 29(5): 1180-1190, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37142763
18.
Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps.
J Allergy Clin Immunol Pract
; 10(4): 1086-1095.e5, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34628065
19.
Patient satisfaction with a pressurized metered-dose inhaler with an integrated dose counter containing a fixed-dose mometasone furoate/formoterol combination.
J Asthma
; 48(6): 625-31, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21726121
20.
Effects of inhaled mometasone furoate on growth velocity and adrenal function: a placebo-controlled trial in children 4-9 years old with mild persistent asthma.
J Asthma
; 48(8): 848-59, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21854342